[Effect of thymus preparations and anti-tuberculosis agents on immunologic reactivity and the course of the tuberculosis process in experimental animals].
Demidov. S V SV; Miasnikov. V G VG; Chernushenko. E F EF; Osipova. L S LS
Key Findings
- Thymogen plus TB drugs increased mouse lifespan compared to drugs alone
- T‑cell counts and proliferative activity rose with thymus peptide treatment
- The thymogen + vilosen combo gave the strongest benefit, while vilosen alone was least effective
Practical Outcomes
- The data hint that thymogen could strengthen immune function during serious infections, but because it’s an animal study on TB, it isn’t a ready‑to‑use protocol for humans. Biohackers should treat this as early‑stage evidence and wait for human trials before considering supplementation.
Summary
In a mouse study, adding thymus‑derived peptides like thymogen to standard TB drugs helped the animals live longer, reduced disease severity, and boosted their T‑cell numbers and activity. Thymogen worked best, especially when paired with another peptide, vilosen, but the research was done in mice with tuberculosis, not people.
Abstract
The effects of thymogen, thymalin and vilosen in combination with antituberculous drugs (isoniazid, streptomycin, rifampicin) were studied on 240 CBA mice with experimental tuberculosis. Thymus preparations supplemented to the complex treatment of experimental tuberculosis significantly increased their lifespan, contributed to a decrease in the index of spleen weight lung density and significantly increased the count of T lymphocytes and their proliferative activity as compared to those on antituberculous drugs alone. Thymogen was found to be the most effective in the complex treatment of experimental tuberculosis, whereas vilosen was the least. Thymogen plus vilosen proved to be the most beneficial combination of drugs.
Study Information
pubmed
1991